A small clinical trial has shown positive results for a new approach to CAR-T therapy where immune cells are genetically engineered inside the patient's body, rather than externally. The therapy was effective in easing symptoms of Multiple Sclerosis, potentially offering a faster and cheaper way to treat autoimmune diseases.